The widely used Roche Holding AG cancer drug Avastin failed to prolong survival when added to chemo-radiation therapy for glioblastoma - a fast-growing type of brain tumor - according to data presented on Sunday.
Those who received Avastin in the late-stage study of 637 previously untreated patients also experienced more side effects, such as low platelet counts, blood clots and elevated blood pressure. Researchers said the toxicity was not severe enough to preclude use of Avastin, or bevacizumab, had it helped patients live longer.
No comments:
Post a Comment